-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In recent years, due to changes in life>
.
In the face of the continuous improvement of the market development prospects of diabetes, domestic pharmaceutical companies are stepping up to enter the market one after another
.
Affected by this, good news such as the listing and over-review of hypoglycemic drugs in the domestic market also began to spread
.
Chengdu Hengrui Pharmaceutical and Jiangxi Pharmaceutical Gliclazide Sustained-Release Tablets have been reviewed.
Zite sustained-release tablets have been approved and reviewed with supplementary applications
.
The data show that Gliclazide extended-release tablets are mainly used for non-islet-dependent diabetes mellitus when dietary therapy alone is insufficient to control blood sugar, and its blood sugar lowering intensity is between tolbutamide and excellent blood sugar
.
Data shows that in 2021, the sales of terminal Gliclazide sustained-release tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be nearly 1.
2 billion yuan, of which Servier market.
The share is relatively large, accounting for more than 50%
.
Currently, 22 companies have the production approval for Gliclazide extended-release tablets
.
In addition, 3 companies including China Resources Shuanghe Limin Pharmaceutical (Jinan) and Ningbo Keerkang Minovar Pharmaceutical submitted their marketing applications under the category 4 imitations.
The supplementary application for sexual evaluation is also under review and approval
.
Lepu Pharmaceutical's Sitagliptin Phosphate Tablets Approved Recently, the website of the State Food and Drug Administration shows that Lepu Pharmaceuticals has been approved as a generic version of Sitagliptin Phosphate Tablets, and it is regarded as an over-evaluation
.
It is understood that sitagliptin, developed by Merck & Co.
, is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor.
Compared with traditional hypoglycemic drugs, this class of drugs does not increase the risk of hypoglycemia.
, Neutral impact on body weight, good cardiovascular safety and other advantages
.
In 2021, the global sales of sitagliptin will exceed 3 billion US dollars; in recent years, the sales in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities have grown rapidly, with a total of more than 1.
5 billion yuan in 2020
.
At present, 12 companies have production approvals for sitagliptin phosphate tablets; in addition, more than 10 companies including Jiangsu Wanbang Biochemical Pharmaceutical, Yantai Luyin Pharmaceutical, and Zhejiang Nuode Pharmaceutical have also submitted their listing applications and are under review and approval
.
Shandong New Era Pharmaceuticals' Metformin Hydrochloride Sustained-Release Tablets Approved for Marketing On April 15, NMPA released drug approval information showing that Shandong New Era Pharmaceuticals' metformin hydrochloride sustained-release tablets 4 categories of generic marketing applications were approved
.
Data show that metformin is the first-line drug for the treatment of type 2 diabetes
.
In 2020, in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, metformin has become a major non-insulin hypoglycemic drug, with sales exceeding 6.
2 billion yuan
.
Conclusion Affected by the aging of the population, the improvement of living standards and unhealthy life>
.
The industry believes that with the entry of more and more companies, the competition in the hypoglycemic drug market will become more and more intense
.
At the same time, the replacement of original research by generic drugs in China's hypoglycemic drug market will also accelerate
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
.
In the face of the continuous improvement of the market development prospects of diabetes, domestic pharmaceutical companies are stepping up to enter the market one after another
.
Affected by this, good news such as the listing and over-review of hypoglycemic drugs in the domestic market also began to spread
.
Chengdu Hengrui Pharmaceutical and Jiangxi Pharmaceutical Gliclazide Sustained-Release Tablets have been reviewed.
Zite sustained-release tablets have been approved and reviewed with supplementary applications
.
The data show that Gliclazide extended-release tablets are mainly used for non-islet-dependent diabetes mellitus when dietary therapy alone is insufficient to control blood sugar, and its blood sugar lowering intensity is between tolbutamide and excellent blood sugar
.
Data shows that in 2021, the sales of terminal Gliclazide sustained-release tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be nearly 1.
2 billion yuan, of which Servier market.
The share is relatively large, accounting for more than 50%
.
Currently, 22 companies have the production approval for Gliclazide extended-release tablets
.
In addition, 3 companies including China Resources Shuanghe Limin Pharmaceutical (Jinan) and Ningbo Keerkang Minovar Pharmaceutical submitted their marketing applications under the category 4 imitations.
The supplementary application for sexual evaluation is also under review and approval
.
Lepu Pharmaceutical's Sitagliptin Phosphate Tablets Approved Recently, the website of the State Food and Drug Administration shows that Lepu Pharmaceuticals has been approved as a generic version of Sitagliptin Phosphate Tablets, and it is regarded as an over-evaluation
.
It is understood that sitagliptin, developed by Merck & Co.
, is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor.
Compared with traditional hypoglycemic drugs, this class of drugs does not increase the risk of hypoglycemia.
, Neutral impact on body weight, good cardiovascular safety and other advantages
.
In 2021, the global sales of sitagliptin will exceed 3 billion US dollars; in recent years, the sales in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities have grown rapidly, with a total of more than 1.
5 billion yuan in 2020
.
At present, 12 companies have production approvals for sitagliptin phosphate tablets; in addition, more than 10 companies including Jiangsu Wanbang Biochemical Pharmaceutical, Yantai Luyin Pharmaceutical, and Zhejiang Nuode Pharmaceutical have also submitted their listing applications and are under review and approval
.
Shandong New Era Pharmaceuticals' Metformin Hydrochloride Sustained-Release Tablets Approved for Marketing On April 15, NMPA released drug approval information showing that Shandong New Era Pharmaceuticals' metformin hydrochloride sustained-release tablets 4 categories of generic marketing applications were approved
.
Data show that metformin is the first-line drug for the treatment of type 2 diabetes
.
In 2020, in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, metformin has become a major non-insulin hypoglycemic drug, with sales exceeding 6.
2 billion yuan
.
Conclusion Affected by the aging of the population, the improvement of living standards and unhealthy life>
.
The industry believes that with the entry of more and more companies, the competition in the hypoglycemic drug market will become more and more intense
.
At the same time, the replacement of original research by generic drugs in China's hypoglycemic drug market will also accelerate
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
